“Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity & Clinical Trials Insight 2026” Report Highlights: • Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026.
New York, Aug. 19, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the publication of the report “Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity & Clinical Trials Insight 2026” – https://www.reportlinker.com/p06128247/?utm_source=GNW
• Role of FGFR inhibitors in cancer therapy
• Global FGFR Market Assessment (US$) by Regions and Cancer Type
• Clinical and sales insights on approved FGFR inhibitors: 3 (Belvesra, Pemazyre & Truseltiq)
• Insight into dosage and drug price of approved FGFR inhibitors
• Comprehensive clinical trials Insights by company, country, stage and patient segment: 53 drugs in trials
🎬📺 Free Movies and Free TV Shows! 🎭🎬
Recent breakthroughs in small molecule therapy in the oncology segment have yielded remarkable results in terms of improving cancer survival rates. The FGFR inhibitors are regarded as one of the advanced anti-cancer therapies, which belongs to the class of receptor kinase-inhibiting small molecules and now widely accepted for the treatment of various cancers including bladder cancer, breast cancer, lung cancer, stomach cancer, lymphoma, myeloma etc. In a short period of time, FGFR inhibitors have passed all the challenges and led to a stage where the availability of the therapy is highly valued and praised.
The mutation or overexpression of FGFR makes them an ideal target for cancer treatment, and most of the researchers investigating the therapeutic potential of this class came to the conclusion that this approach has beneficial effects. Furthermore, the FGFR changes are also observed in rare cancers and therefore this approach may play a crucial role in the treatment of untreatable rare cancers. Currently, the market of FGFR inhibitors is in a nascent phase, which is driven by the sale of 3 approved products of this class, namely Balversa, Pemazyre and Truseltiq. Balversa is recommended for the treatment of bladder cancer, while Pemazyre and Truseltiq are recommended for the treatment of a rare cancer called cholangiocarcinoma. It is believed that many new drugs of this class will receive orphan drug status in the coming years, further increasing the market size of this segment.
Balversa is expected to lead the market segment as sales value is expected to grow exponentially after approval in the leading regions, including Europe and Japan. The estimated market size of FGFR Inhibitor is about US$100 million in the year 2020 and it is believed to grow at a CAGR of over 80% over the next 6 years as most of the market related factors point to the increasing adoption of this segment in the near future. Furthermore, the US will lead the FGFR market due to the availability of a huge cancer burden and leading pharmaceutical companies. The drug approval process has now been simplified in the US due to the availability of all three drugs of this class and therefore most new FGFR inhibitors will receive approval in this region first.
With the aim of improving the market penetration and commercialization of FGFR inhibitors, the leading pharmaceutical companies are expected to collaborate with CROs and regional pharmaceutical companies of development companies, which will increase the market size of this new segment in regions such as Asia-Pacific, Middle East and Latin America. The leading pharmaceutical companies operating in this sector are Amgen, Astem pharma, AstraZenca, Bayer, BMS, Incyte, Roche, Taiho, Janssen Pharmaceuticals, Novartis etc. while many other companies are working on FGFR inhibitors in preclinical studies.
The report “Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity & Clinical Trials Insight 2026” includes an in-depth analysis of the various parameters related to this segment along with the analysis of both current and future market opportunities. The report also analyzes the wide range of applications of this class in the field of cancer management along with the clinical trends, market drivers, and potential challenges related to the FGFR Inhibitors market. Furthermore, multiple parameters are considered to predict and analyze the global, regional, and indications-based FGR Inhibitors market size.
Read the full report: https://www.reportlinker.com/p06128247/?utm_source=GNW
As regards Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data, so you get all the market research you need instantly and in one place.
CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001